NCT03542305View on ClinicalTrials.gov

Lorlatinib Renal Impairment Study

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

February 20, 2020

Study Completion Date

February 20, 2020

Conditions

Renal Impairment

Interventions

DRUG

Lorlatinib

Lorlatinib single oral dose

Trial Locations (2)

55114

Prism Clinical Research, LLC, Saint Paul

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY